Beyond What Exists - Discovering What’s Possible

Our products focus on current & emerging needs

Better Input. Better Outcomes.

Insight. Effort. Results. These three words summarize Endo Pharmaceuticals. We listen to patients and doctors. We build on what we learn. And we collaborate with our partners to create innovative drugs and delivery systems. Solutions that inspire the medical, economic and practical outcomes we all want. It's this unique combination of forces that drives Endo Pharmaceuticals beyond what exists—to discover what's possible.

Investor Information

ENDP (Common Stock)





-0.08 (-0.09%)

Auxilium Pharmaceuticals

Endo recently completed the acquisition of Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company.

Therapeutic Areas

Pain Management

We believe pain management should be more than a goal. That's why we made it one of our specialties.

Learn More


We focus on many urological medical problems people are facing today: Low testosterone, erectile dysfunction, Peyronie's disease, bladder cancer and prostate cancer.

Learn More


We're dedicated to meeting the needs of children and families affected by central precocious puberty (CPP).

Learn More


We provide a solution for patients diagnosed with Dupuytren's contracture where a cord can be felt.

Learn More

Career Opportunities

MA HCP Opt-Out Request Form

Massachusetts prescribers may opt-out of future Endo Pharmaceuticals communications by completing the MA HCP Opt-Out Request Form.

About Endo


Endo International plc is a global specialty healthcare company focused on improving patients' lives while creating value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic pharmaceutical, over the counter medications and medical device products through its operating companies: Endo Pharmaceuticals, Qualitest, AMS, Paladin Labs and SOMAR.

Endo has global headquarters in Dublin, Ireland and US headquarters in Malvern, PA.